YU2500A - Alatrofloksacin parenteralni preparati - Google Patents

Alatrofloksacin parenteralni preparati

Info

Publication number
YU2500A
YU2500A YU2500A YU2500A YU2500A YU 2500 A YU2500 A YU 2500A YU 2500 A YU2500 A YU 2500A YU 2500 A YU2500 A YU 2500A YU 2500 A YU2500 A YU 2500A
Authority
YU
Yugoslavia
Prior art keywords
alatrofloxacin
parenteral compositions
alatrofloxacin mesylate
mesylate
purifying
Prior art date
Application number
YU2500A
Other languages
English (en)
Inventor
Robert Mark Guinn
John Francis Lambert
Subramanian Sam Guhan
Stanley Walter Walinsky
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU2500A publication Critical patent/YU2500A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Predmetni pronalazak se odnosi na alatrofloksacin mezilat uglavnom bez manje polarnih nečistoća, na parenteralne preparate alatrofloksacin mezilata i na postupke za prečišćavanje alatrofloksacin mezilata.[The present invention relates to alatrofloxacin mesylate substantially free of less polar impurities, to parenteral compositions of alatrofloxacin mesylate and to processes for purifying alatrofloxacin mesylate.
YU2500A 1997-08-01 1998-07-23 Alatrofloksacin parenteralni preparati YU2500A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5424697P 1997-08-01 1997-08-01

Publications (1)

Publication Number Publication Date
YU2500A true YU2500A (sh) 2002-09-19

Family

ID=21989735

Family Applications (1)

Application Number Title Priority Date Filing Date
YU2500A YU2500A (sh) 1997-08-01 1998-07-23 Alatrofloksacin parenteralni preparati

Country Status (40)

Country Link
US (1) US6194429B1 (sh)
EP (1) EP1000086B1 (sh)
JP (1) JP3463928B2 (sh)
KR (1) KR20010022495A (sh)
CN (1) CN1265671A (sh)
AP (1) AP1031A (sh)
AR (1) AR015417A1 (sh)
AT (1) ATE259827T1 (sh)
AU (1) AU734863B2 (sh)
BG (1) BG104105A (sh)
BR (1) BR9811580A (sh)
CA (1) CA2296466C (sh)
CO (1) CO4970688A1 (sh)
DE (1) DE69821767T2 (sh)
DK (1) DK1000086T3 (sh)
DZ (1) DZ2576A1 (sh)
EA (1) EA002120B1 (sh)
ES (1) ES2214716T3 (sh)
GT (1) GT199800112A (sh)
HN (1) HN1998000106A (sh)
HR (1) HRP980417B1 (sh)
HU (1) HUP0004793A3 (sh)
ID (1) ID24374A (sh)
IL (1) IL134156A0 (sh)
IS (1) IS5339A (sh)
MA (1) MA24626A1 (sh)
NO (1) NO20000485L (sh)
NZ (1) NZ502249A (sh)
OA (1) OA11281A (sh)
PA (1) PA8456701A1 (sh)
PE (1) PE103799A1 (sh)
PL (1) PL338477A1 (sh)
PT (1) PT1000086E (sh)
SK (1) SK1012000A3 (sh)
TN (1) TNSN98146A1 (sh)
TW (1) TW538043B (sh)
UY (1) UY25113A1 (sh)
WO (1) WO1999006430A1 (sh)
YU (1) YU2500A (sh)
ZA (1) ZA986874B (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2387016C (en) * 1999-10-08 2010-09-28 William H. Miller Acrylamide derivatives as fab i inhibitors
EP1121933A1 (en) * 2000-02-02 2001-08-08 Pfizer Products Inc. Premixed alatrofloxacin injectable compositions
DK1560584T3 (da) 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitorer
JP4859460B2 (ja) * 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
DK1828167T3 (da) 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
EP2125802A4 (en) * 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
IN2014KN02915A (sh) 2012-06-19 2015-05-08 Debiopharm Int Sa
EP3689362A1 (en) * 2014-04-25 2020-08-05 Naurex, Inc. Stable compositions of neuroactive peptides
TN2018000293A1 (en) 2016-02-26 2020-01-16 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
KR20200121816A (ko) 2018-02-02 2020-10-26 리플 테라퓨틱스 코포레이션 스테로이드 이량체를 포함하는 유리 제제 및 이의 용도
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3713672A1 (de) 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5256791A (en) 1992-03-02 1993-10-26 Pfizer Inc. Preparation of intermediates in the synthesis of quinoline antibiotics
RU2147303C1 (ru) 1994-01-18 2000-04-10 Пфайзер Инк. Промежуточные продукты и способ получения солей нафтиридонкарбоновой кислоты
TW420610B (en) 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
US5475116A (en) 1994-04-29 1995-12-12 Pfizer Inc. Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones
DK0789697T3 (da) 1995-06-06 1998-10-19 Pfizer Krystalform af vandfrit 7-([1alfa, 5alfa, 6alfa,]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-fluor-1-(2,4-difluorphenyl)-1,4-d
JP3029293B2 (ja) * 1995-06-15 2000-04-04 ファイザー・インコーポレーテッド ジペプチドを含む、アザビシクロナフチリジンカルボン酸の誘導体を調製するための方法
PL325170A1 (en) 1995-08-29 1998-07-06 Pfizer Bipolar forms of throwaflocacin
PL185709B1 (pl) 1995-08-29 2003-07-31 Pfizer Nowy monohydrat polimorfu II 6-N-(L-Ala-L-Ala)-trowafloksacyny i środek farmaceutyczny
GB9524466D0 (en) 1995-11-30 1996-01-31 Pfizer Ltd Process
JPH1087617A (ja) 1996-07-09 1998-04-07 Pfizer Inc キノリン系抗生物質の合成に有用な中間体の製法

Also Published As

Publication number Publication date
PT1000086E (pt) 2004-05-31
UY25113A1 (es) 2000-12-29
PA8456701A1 (es) 2000-05-24
EP1000086A1 (en) 2000-05-17
MA24626A1 (fr) 1999-04-01
PL338477A1 (en) 2000-11-06
TW538043B (en) 2003-06-21
ATE259827T1 (de) 2004-03-15
HUP0004793A2 (hu) 2001-04-28
JP3463928B2 (ja) 2003-11-05
WO1999006430A1 (en) 1999-02-11
BR9811580A (pt) 2000-08-22
DZ2576A1 (fr) 2003-02-22
NO20000485L (no) 2000-03-27
OA11281A (en) 2002-11-19
DE69821767T2 (de) 2005-01-13
JP2001512133A (ja) 2001-08-21
NZ502249A (en) 2001-11-30
CA2296466A1 (en) 1999-02-11
ID24374A (id) 2000-07-13
GT199800112A (es) 2000-01-15
EA200000086A1 (ru) 2000-08-28
DK1000086T3 (da) 2004-05-17
HUP0004793A3 (en) 2001-10-29
AU8236898A (en) 1999-02-22
CN1265671A (zh) 2000-09-06
CO4970688A1 (es) 2000-11-07
ZA986874B (en) 2000-01-31
AP9801310A0 (en) 1998-09-30
HN1998000106A (es) 1999-01-08
EP1000086B1 (en) 2004-02-18
US6194429B1 (en) 2001-02-27
HRP980417A2 (en) 1999-08-31
ES2214716T3 (es) 2004-09-16
DE69821767D1 (de) 2004-03-25
AR015417A1 (es) 2001-05-02
TNSN98146A1 (fr) 2005-03-15
CA2296466C (en) 2003-04-15
AP1031A (en) 2001-12-21
AU734863B2 (en) 2001-06-21
BG104105A (bg) 2000-08-31
SK1012000A3 (en) 2000-09-12
NO20000485D0 (no) 2000-01-31
IS5339A (is) 2000-01-14
IL134156A0 (en) 2001-04-30
KR20010022495A (ko) 2001-03-15
PE103799A1 (es) 1999-10-25
HRP980417B1 (en) 2002-10-31
EA002120B1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
YU2500A (sh) Alatrofloksacin parenteralni preparati
MX9703430A (es) Uso de dioxomorfolinas para la lucha contra endoparasitos, nuevas dioxomorfolinas y procedimiento para su produccion.
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
UA39099C2 (uk) Циклічні азотовмісні похідні, суміш їх ізомерів або окремі ізомери, або їх солі
MY134559A (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
WO2000035919A3 (en) Quinoline derivatives
BG102644A (en) Improved concentrated inoculation and infusion solutions for intravasal application
MXPA02004666A (es) Gelatinas recombinantes.
CA2241787A1 (en) Substituted aza- and diazacycloheptane and cyclooctane compounds and their use
NZ503308A (en) Alpha-ketoamide multicatalytic protease inhibitors
BG103914A (en) Maintained separation of delayed gels
GB0011203D0 (en) Chemical compounds
MXPA04004939A (es) 5,5??,6,6??,7,7??,8,8??-octahidro-2,2??-binaftoles 3-alquilados y 5,5??,6,6??,7,7??,8,8??-octahidro-2,2??-binaftoles 3,3??-dialquilados y procesos para su fabricacion.
IL109720A (en) N-alkylthio polyamine derivatives and radioprotective compositions containing them
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
ZA961364B (en) 1-Aryl-2-acylamino-ethane compounds
CA2166692A1 (en) Novel 9-n-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
MX9801190A (es) Inhibidores de prolil endopeptidasa.
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
CA2270301A1 (en) Hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for their preparation
IL138638A0 (en) Processes for preparing intermediates
NO20002191L (no) Dofetilid polymorfer
AU2002224322A1 (en) Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease
PL343758A1 (en) Purification of carboxaldehyde
MY117392A (en) Monocyclic compounds with four bifunctional residues having nk-2 antagonist action